Table 2.
IL-4 lota | Conditionsb | Activationc | Mouse straind | Lytic units per 106CTLs | Lipid enhancementg | |
---|---|---|---|---|---|---|
IL-4 CTLse | IL-4 CTLs + lipidf | |||||
BD:83653 | 1500 U/ml IL-4 | ConA | Balb/c WT | 16031 | 16950 | 1.1 |
eBio:E031047 | 1500 U/ml IL-4 | ConA | Balb/c perforin KO | 23246 | 31979 | 1.4 |
eBio:E031047 | 500 U/ml IL-4 | ConA | IFNg receptor KO B6 | 26246 | 16407 | 0.6 |
eBio:E031047 | 500 U/ml IL-4 + anti-IL-12 | ConA | IFNg receptor KO B6 | 46398 | 16408 | 0.4 |
eBio:E031047 | 500 U/ml IL-4 | Anti-CD3/CD28 | C57B6 | 30063 | 27780 | 0.9 |
eBio:E031047 | 500 U/ml IL-4 | Anti-CD3/CD28 | C57B6 | 23088 | 27931 | 1.2 |
eBio:E031047 | 500U/ml IL-4 + 400U/ml IFNg | ConA | C57B6 | 3543 | 1351 | 0.4 |
Lot of IL-4.
Concentrations of cytokine during induction of T cells.
Method of T cell activation.
Mouse strain and genetic modifications.
Lytic units per 10M CTLs for IL-4 induced CTLs assayed without triglycerides.
Lytic units per 10M CTLs for IL-4 induced CTLs assayed with triglycerides.
Ratios of the lytic activity of CTLs assayed in the presence of lipid compared to CTLs without lipid.